Company / PP&E (Net)
FATE THERAPEUTICS INC PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$56.9M
FY2025
5-year range
$56.9M / $110.0M
FY2021-FY2025
Trend
-11.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 3 consecutive years, from $110M in FY2022 to $57M in FY2025.
Based on SEC 10-K filings.
$57M in FY2025 with a 5-year CAGR of +12.0%.
Declined from $97M to $57M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -19.7%
- 5-Year CAGR
- +12.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- FATE THERAPEUTICS INC's pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of +12.0%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 11.6% year-over-year.
- Peak pp&e (net) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $56.9M | -11.6% |
| FY2024 | $64.4M | -33.5% |
| FY2023 | $96.8M | -12.0% |
| FY2022 | $110.0M | +20.2% |
| FY2021 | $91.5M | +183.3% |
| FY2020 | $32.3M | +182.9% |
| FY2019 | $11.4M | +122.8% |
| FY2018 | $5.1M | +101.0% |
| FY2017 | $2.5M | +61.5% |
| FY2016 | $1.6M | -26.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026